Development of repaglinide loaded solid lipid nanocarrier: Selection of fabrication method

Current Drug Delivery

Volumn 7, Issue 1, 2010, Pages 44-50

  Rawat, M K ^a   Jain, A ^a   Mishra, A ^a   Muthu, M S ^b   Singh, S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Bioavaiability; Colloidal dispersion; Modified solvent injection technique; Oral route; Ultrasonication

Indexed keywords

DRUG CARRIER; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLCHOLINE; REPAGLINIDE; STEARIC ACID;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ZETA POTENTIAL;

BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMATES; DRUG CARRIERS; HYPOGLYCEMIC AGENTS; LIPIDS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; PARTICLE SIZE; PIPERIDINES;

EID: 77949747766     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110790396472     Document Type: Article

References (33)

1. Mehnert, W; Mader, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47, 165-196.
2. Venkateswarlu, V.; Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control Release., 2004, 95, 627-638.
3. Muller, R.H.; Runge, S.; Ravelli, V.; Mehnert, W.; Thunemann, A.F.; Souto, E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm., 2006, 317, 82-89.
4. Li, H.; Zhao, X.; Ma, Y.; Zhai, G.; Li, L.; Lou, H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release, 2009, 133, 238-244.
5. Holm, R.; Mullertz, A.; Christensen, E.; Hoy, C.E.; Kristensen, H.G. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci., 2001, 14, 331-337.
6. Porter, C.J.H.; Charman, S.A. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci., 2003, 89, 297-310.
7. Demirel, M.; Yazan, Y.; Muller, R.H.; Kilic, F.; Bozan, B. Formulation and in vitro-in vivo evaluation of piribidil solid lipid micro and nanoparticles. J.Microencapsul., 2001, 18(3), 359-71.
8. Cavalli, R.; Bargoni, A.; Podio, V.; Muntoni, E. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci., 2003, 92, 1085-1094.
9. Kumar, V.V.; Chandrasekar, D. S.V. Ramakrishna, Kishan, V.; Rao, Y.M.; Diwan, P.V. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics, Int. J. Pharm., 2007, 335 , 167-175.
10. Yang, L.; Geng, Y.; Li, H.; Yu, Z.; You, J.; Chang, Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmzie., 2009, 64(2), 86-89.
11. Mayer-Davis E.J.; Levin, S.; Bergman, R.N.; D'Agostino, R.B.; Karter, A.J.; Saad, M.F. Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab. Res. Rev., 2001, 17, 137-145.
12. Rizzo, M.R.; Barbieri, M.; Grella, R.; Passariello, N.; Paolisso, G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab., 2005, 31, 255-260.
13. Nattrass, M.; Bailey, C.J. New agents for Type 2 diabetes. Baillieres Clin. Endocrinol. Metab., 1999, 13, 309-329.
14. Jain, S.K.; Agrawal, G.P.; Jain, N.K. A novel calcium silicate based microspheres of repaglinide: in vivo investigations. J. Control Release, 2006, 113, 111-116.
15. Skaug, V.; Davies, R.; Gylseth, B. In vitro macrophage cytotoxicity of five calcium silicates. Br. J. Ind. Med., 1984, 41, 116-121.
16. Hauss, D.J. Oral lipid-based formulations. Adv. Drug. Deliv. Rev., 2007, 59, 667-676.
17. Mandic , Z.; Gabelica, V. Ionization, lipophilicity and solubility properties of repaglinide. J. Pharm. Biomed. Anal., 2006, 41, 866-871.
18. Schwarz, C.; Mehnert, W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int. J. Pharm., 1997, 157, 171-179.
19. Freitas, X.; Muller, R.H. Spray-drying of solid lipid nanoparticles (SLN TM). Eur. J. Pharm. Biopharm., 1998, 46, 145-151.
20. Heiati, H.; Tawashi, R.; Phillips, N.C. Drug retention and stability of solid lipid nanoparticies containing azi-dothymidine palmitate after autoclaving, storage and lyophilization. J. Microencapsul., 1998, 15, 173-184.
21. Freitas, X.; Muller, R.H. Correlation between long- term stability of solid lipid nanoparticles (SLN) and crys-tallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47, 125-132.
22. Schubert, M.A.; Muller-Goymann, C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur. J. Pharm. Biopharm., 2003, 55, 125-131.
23. Domb, A.J. Lipospheres for controlled delivery of sub- stances. United States Patent, USS, 188837, 1993.
24. Verger, M.L.; Fluckiger, L.; Kim, Y. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur. J. Pharm. Biopharm., 1998, 46, 137-143.
25. Moneghini, M.; Volinovich, D.; Princivalle, F. Formulation and evaluation of vinypyrrolidone/vinylacetate copolymer microspheres with carbamazepine. Pharma. Dev. Technol., 2000, 5, 347-353.
26. Quintanar-Guerrero, D.; Allemann, E.; Doelker, E.; Fessi, H. A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique. Colloid Polym. Sci., 1997, 275, 640-647.
27. Schubert, M. A.; Muller-Goymann, C. C. Solvent injection as a new approach for manufacturing lipid nanoparticles: evaluation of the method and process parameters. Eur. J. Pharm. Biopharm., 2003, 55, 125-131.
28. Grieser, F.; Ashokkumar, M.; Sostaric, J.Z. Sonochemistry and Sonoluminescence in Colloidal Systems. In: Crum, L.A.; Mason, T.J.; Reisse J.L.; Suslick, K.S. Eds.; Kluwer Academic Publishers, Netherlands, 1999; Vol. 1, pp. 345- 362.
29. Muthu, M.S.; Singh, S. Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine., 2008, 3, 305-319.
30. Betancourt, T.; Brown, B.; Brannon-Peppas, L. Doxorubicin - loaded PLGA nanoparticles by nanoprecipitation: Preparation, characterization and in vitro evaluation. Nanomedicine, 2007, 2, 219-232.
31. Washington, C. Drug release from microdisperse systems. A critical review. Int. J. Pharm., 1990, 58, 1-12.
32. Cavalli, R.; Aquilano, D.; Carrlotti, M.E.; Gasco, M.R. Study by Xray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles. Eur. J. Pharm. Biopharm., 1995, 41, 329-333.
33. Hu, F.Q.; Jiang, S.-P.; Du, Y.-Z.; Yuan, H.; Ye, Y.Q.; Zeng, S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B: Biointerfaces., 2005, 45, 167-173.